Role of the Immune Environment in Response to Therapy in Breast Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT05396612
Status
Recruiting
Apply to this trial

Conditions

  • Breast Cancer
  • ER Positive Breast Cancer
  • HER2-negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. — OTHER
    Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Study Details

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Key Dates

Start date
Oct 3, 2022
Status verified
Jul 2025
Primary completion
Dec 31, 2032
Completion
Dec 31, 2032

Study Design

Enrollment
300 participants (estimated)

Primary Outcome Measure

Collecting, processing and archiving breast cancer tumor tissues [ Time Frame: Through study completion, average of 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer CenterPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Abramson Cancer Center· Philadelphia, PA

Related Studies